US FDA seeks more data from Transcept's insomnia drug Intermezzo
Saturday, October 31, 2009 11:00 IST Richmond, California
Transcept Pharmaceuticals announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo (zolpidem tartrate sublingual tablet).
